US Gilead Company to sell its Sovaldi treatment to Egypt

CAIRO: The agreement to offer the Solvadi treatment created by American organization Gilead to Egypt incorporating furnishing Egypt with 225 thousand measurements of the treatment as a first shipment for 450 million EGP ($63 million) was inevitably marked, Minister of Health Adel el-Adway declared in a public interview on Tuesday, al-Shorouk reported.

Adawy said that the agreement is elite to Egypt and that Egypt purchased the treatment for one percent of its unique global cost. He additionally included that this won't be the last contract with respect to medicines that demonstrate their viability and said that the entryway is generally open for Egyptian pharmaceutical organizations to substantiate themselves and produce a 100 percent Egyptian medication and register it, al-Shorouk included.

The assembling organization is qualified for give the treatment to the 26 authority drug outlets of the National Commission for hepatic infections and the treatment would be accessible for the individuals who are secured by medical coverage and the individuals who are not, al-Wafd reported Tuesday.

The strategy to enroll the treatment in the service of wellbeing and indicate its cost in the general business sector is done. The treatment will be accessible for patients in September, al-Wafd included.

An advisory group of 100 specialists will meet to choose who is qualified for treatment and what cases ought to be taken care of first. The investigations held in Egypt on the Hepatitis C infection demonstrated that the treatment cures the infection with a win rate of more than 90 percent which is a decent rate, al-Wafd reported.

"This is a memorable day for Egypt and patients with liver ailments," the priest said at the meeting as indicated by Aswat Masreya. He additionally included that the first cost of the treatment which goes on for three months costs 84 thousand USD and Egypt purchased it for one percent of its unique cost, Aswat Masreya included.

Gregg Alton, the head of corporate and medicinal issues at Gilead, said in an announcement "We trust Sovaldi could have a noteworthy effect on general wellbeing in Egypt by fundamentally expanding the quantity of individuals who can be cured of hepatitis C," as per Reuters on April 23, 2014.

On March 12, Minister of Health Adel Adawy announced in an announcement that the transactions between the service and the American organization were effective and Egypt will acquire the medication for just 1 percent of its cost, by Masry Al-Youm.

Egypt tops the rundown of hepatitis C contamination globally and in the Arab world, disease rate in Egypt speaks the truth 14 percent of the populace, said an individual from the American Association of Liver Treatment, Dr. Ali Moanes told al-Shark al-Awsat daily paper on February 8, 2013.